Mental Health Clinics in Angleton, TX Accepting Medicare
8 Mental Health Clinics found. Showing 1 - 8
 Garza Counseling And Associates Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 120 E Plum St, Angleton, TX 77515 Phone: 979-549-0889 Fax: 979-549-0878 |
Brazoria County Counseling Center, Llc Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 120 E Plum St, Angleton, TX 77515 Phone: 281-910-0921 |
Resolution Counseling & Educational Services Pllc Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 4005 Technology Rd Ste 1008g, Angleton, TX 77515 Phone: 979-319-0713 |
Bee Empowered Counseling And Educational Services, Pllc Counselor Medicare: Not Enrolled in Medicare Practice Location: 201 E Myrtle St Ste 112, Angleton, TX 77515 Phone: 346-278-9109 |
Intentional Actions A Behavior Analytic Approach Llc Behavioral Analyst Medicare: Not Enrolled in Medicare Practice Location: 120 E Hospital Dr, Angleton, TX 77515 Phone: 281-310-0632 |
Aba In The Right Path Pllc Behavioral Analyst Medicare: Not Enrolled in Medicare Practice Location: 1100 E Mulberry St Ste E, Angleton, TX 77515 Phone: 979-946-4024 Fax: 979-946-4073 |
The Pain Care Center Social Worker - Clinical Medicare: Not Enrolled in Medicare Practice Location: 2327 W Highway 35, Angleton, TX 77515 Phone: 979-848-1886 Fax: 979-848-1376 |
Therapeutic Mind Shift, Llc Social Worker - Clinical Medicare: Not Enrolled in Medicare Practice Location: 222 County Road 608, Angleton, TX 77515 Phone: 979-248-4542 |
News Archive
Gilead Sciences plans to launch authorized generic versions of Epclusa and Harvoni in the US
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
Morria Biopharmaceuticals receives approval to commence its Phase II clinical trial on MRX6
Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced today that it has received written approval to commence its Phase II clinical trial on its leading topical Multi-Functional Anti Inflammatory Drug (MFAID) MRX6.
Medicago included in President's report that examines drugs to prevent spread of infectious diseases
Medicago Inc., a clinical-stage biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that it was included in a report of President Obama's Council of Advisors on Science and Technology entitled "Report to the President on Reengineering the Influenza Vaccine Production Enterprise to Meet the Challenges of Pandemic Influenza", which was released earlier this month. U.S. Health and Human Services Secretary Kathleen Sebelius and other public health officials held a briefing to discuss this report and the $2 billion plan to accelerate the development of drugs and vaccines to prevent the spread of infectious diseases.
Simple blood test can better identify patients at risk of relapse for B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, a cancer that begins in certain immune system cells and can occur almost anywhere in the body. More than 28,000 people are diagnosed with DLBCL each year.
SU11248 proves effective in the treatment of gastrointestinal stromal tumors
A drug originally developed to block the formation of blood vessels in tumors has been shown to overcome resistance to treatment with Gleevec in patients with gastrointestinal stromal tumors (GIST).
› Verified 2 days ago